From pilot to practice: solving life sciences scale-up and facility design challenges

The life sciences sector is experiencing unprecedented pressure to translate scientific breakthroughs into commercial, clinical and manufacturing outcomes. Governments, investors and industry stakeholders increasingly expect research funding to deliver real world impact, particularly in rapidly growing fields such as mRNA therapeutics, cell and gene therapies, advanced biologics and precision medicine.

Yet despite strong science and significant investment, many organisations struggle when moving from research environments through pilot operations and towards Good Manufacturing Practice (GMP) manufacturing facilities. The challenge is rarely the science itself. More often, the obstacle lies in infrastructure planning and facility strategy.

Research laboratories are designed to support flexibility, experimentation and relatively low capital investment. GMP facilities, by contrast, are designed around compliance, repeatability, product quality and operational control. They require carefully managed flows of people and materials, validated systems, environmental controls, segregated utilities and robust quality frameworks.

When organisations fail to recognise these fundamentally different requirements early, projects often encounter avoidable setbacks.

The hidden cost of under-scoping infrastructure

A common challenge emerges during grant applications, investment proposals and early business case development. To maximise affordability or fit within funding constraints, critical infrastructure requirements are frequently underestimated or deferred.

Typical examples include:

• Cleanroom classifications and zoning requirements
• HVAC capacity and redundancy
• Utility segregation
• Waste management systems
• Product and personnel flow requirements
• Validation and commissioning programmes
• Quality management interfaces

At the early stage these omissions may appear manageable. However, as projects mature and regulatory obligations become clearer, these infrastructure gaps become increasingly difficult and costly to address.

The consequences can include:

• Significant redesign costs
• Construction programme delays
• Increased regulatory risks
• Reduced stakeholder confidence
• Funding shortfalls
• Assets that cannot transition to GMP without major retrofit

Many university based translational facilities and emerging biotechnology companies have experienced this exact challenge. Facilities initially intended to support pilot manufacturing ultimately become dead end assets that require extensive modification or replacement before they can meet GMP expectations.

A better approach: planning for scale from day one

Successful scale up requires organisations to think beyond the immediate research programme and establish a clear pathway toward future manufacturing, compliance, and operational requirements.

Rather than treating GMP as a distant future objective, leading organisations incorporate scalability and compliance considerations into early planning and investment decisions. This approach reduces uncertainty, improves funding credibility, and creates facilities capable of evolving alongside scientific and commercial growth.

Wood has developed a structured Pilot to GMP Scale Up framework that brings facility strategy, compliance planning and capital investment decisions together at the earliest stages of project development. By integrating these considerations early, we can reduce the risk of expensive redesigns and avoid creating barriers to future licensing and certification.

The importance of designing for adaptability

One of the most important characteristics of successful life sciences facilities is adaptability.

Scientific programmes change. Technologies evolve. Product pipelines expand. Regulatory expectations continue to develop.

Facilities designed only around today's requirements often become constraints tomorrow. By incorporating flexibility, modularity and future expansion pathways into facility planning, organisations can accommodate change without significant disruption or capital reinvestment.

Facilities that deliver the strongest long-term value are rarely those optimised solely for today's programme. They are designed to accommodate future products, technologies and regulatory expectations.

Plan for scale-up and GMP before you need it

The journey from research to GMP manufacturing is not simply a scientific challenge. It is a strategic infrastructure challenge.

Many scale up failures occur because facilities are designed around immediate research needs rather than future operational, regulatory and manufacturing requirements. The result is costly redesign, delayed programmes and infrastructure that cannot support commercial ambitions.

Organisations that integrate facility planning, compliance strategy and operational readiness from the outset place themselves in a far stronger position to secure funding, deliver projects successfully and achieve sustainable growth.

The most effective scale up strategies do not wait for GMP requirements to emerge, they anticipate them.